
Product Manual

Cell Contraction Assay

Catalog Number

CBA-201

24 assays

FOR RESEARCH USE ONLY
Not for use in diagnostic procedures



CELL BIOLABS, INC.
Creating Solutions for Life Science Research

Introduction

Wound healing comprises of three processes: epithelialization, connective tissue deposition, and contraction. The contraction process is believed to be mediated by specialized fibroblasts called myofibroblasts. Three-dimensional collagen gels have been widely used in fibroblast contraction studies.


There are several different culture models to study the ability of fibroblasts to reorganize and contract collagen matrices in vitro. In the floating contraction model, a freshly polymerized collagen matrix containing cells is released from the culture dish and allowed to float in culture medium, and contraction occurs in the absence of external mechanical load and without appearance of stress fibers in the cells. In the attached model, a polymerized collagen matrix containing cells remains attached to the culture dish during contraction. Mechanical tension develops during contraction, and cellular stress fibers assemble. The two-step model combines an initial period of attached matrix contraction leading to mechanical loading, followed by release of the matrices, resulting in mechanical unloading and further contraction as mechanical stress dissipates.

The signaling mechanisms used by fibroblasts to regulate collagen matrix contraction depend on whether the cells are mechanically loaded or unloaded at the time that contraction is initiated as well as on the growth factor used to initiate contraction. For instance, stimulation of fibroblasts by lysophosphatidic acid (LPA) but not by platelet-derived growth factor (PDGF) causes robust force generation in restrained matrices, whereas LPA and PDGF stimulate floating matrix contraction equally well.

3D collagen matrix has also been used in the studies of integrin signaling, cell apoptosis and cytoskeleton reorganization. Since three-dimensional matrix adhesions differ in structure, localization, and function from two-dimensional adhesions; and therefore, three-dimensional cell-matrix interactions may be more relevant biologically.

Cell Biolabs' Collagen-based Contraction Assay Kit provides a simple system to assess cell contractivity in vitro and screen cell contraction mediators. Each kit provides sufficient quantities to perform up to 24 assays in a 24-well plate. The kit can also be used for culturing cells in a 3D collagen matrix.

Assay Principle



Kit Components

1. Collagen Solution (Part No. 20101): One 10 mL bottle of sterile bovine Type I Collagen at 3.0 mg/mL
2. Neutralization Solution (Part No. 20102): One 0.5 mL tube
3. 5X DMEM Medium (Part No. 20103): One 5 mL bottle
4. 5X PBS (Part No. 20104): One 5 mL bottle
5. 100X Cell Contraction Inhibitor (Part No. 20105): One 1 mL tube of 1M 2, 3-Butanedione Monoxime (BDM) in DMSO

Materials Not Supplied

1. Cells such as fibroblasts
2. Cell culture medium
3. 37°C Incubator, 5% CO₂ atmosphere
4. Sterile Spatula
5. Light microscope
6. Ruler

Storage

Store all components at 4°C.

Preparation of Collagen Gel Working Solution

This kit is designed for samples in a 24-well plate, and may be modified accordingly to suit other culture plate sizes. Keep all solutions ON ICE the entire time.

Important Note: Be sure to pipet all volumes carefully with well-calibrated pipettes. Volumes of each reagent are critical for collagen polymerization.

1. In a cold sterile tube, add the desired amount of Collagen Solution according to the table below. Next, add 5X DMEM medium or 5X PBS to the tube and mix well.
2. Add Neutralization solution, IMMEDIATELY mix and keep the Collagen Gel Working Solution on ice.

Reagents	6 wells	12 wells	24 wells
Collagen Solution	2.385 mL	4.77 mL	9.54 mL
5X Medium or PBS	615 μ L	1.23 mL	2.46 mL
Neutralization Solution	85 μ L	170 μ L	340 μ L
Total	3.085 mL	6.17 mL	12.34 mL

Assay Protocol (Two-Step Collagen Contraction Model)

1. Harvest cells and resuspend in desired medium at $2-5 \times 10^6$ cells/mL.
2. Prepare the collagen lattice by mixing 2 parts of cell suspension and 8 parts of cold Collagen Gel Working Solution.
3. Add 0.5 mL of the cell-collagen mixture per well in a 24-well plate, incubate 1 hr at 37°C.
4. After collagen polymerization, 1.0 mL of culture medium is added atop each collagen gel lattice.
5. Cultures are incubated for two days, during which stress develops. Before releasing the stressed matrix, cells may be treated with contraction mediators, such as 10 mM BDM. To initiate contraction, gently release collagen gels from the sides of the culture dishes with a sterile spatula.
6. The collagen gel size change (contraction index) can be measured at various times with a ruler or quantified with image analysis software, such as NIH Image or Image Pro Plus.

Example of Results

The following figure demonstrates typical contraction results using the Cell Contraction Assay. One should use the data below for reference only. This data should not be used to interpret actual results.




Figure 1. Contraction inhibition by BDM. 0.5×10^6 COS-7 cells in 0.5 mL collagen gel lattice were cultured for two days. Before initiation of contraction, cells were pretreated with 10 mM BDM for 1 hr. The change of gel size (diameter) in millimeters was measured with a ruler at various times after release.

References

1. Martin, P. (1997) *Science* **276**, 75-81
2. Bell, E., Ivarsson, B., and Merrill, C. (1979) *Proc. Natl. Acad. Sci. U. S. A.* **76**, 1274-1278
3. Stupak, D., and Harris, A. K. (1982) *Dev. Biol.* **90**, 383-398
4. Mochitate, K., Pawelek, P., and Grinnell, F. (1991) *Exp. Cell Res.* **193**, 198-207
5. Tian, B., Lessan, K., Kahm, J., Kleidon, J., and Henke, C. (2002) *J. Biol. Chem.* **277**, 24667-24675

Recent Product Citations

1. Liu, P. et al. (2021). Fasudil Dichloroacetate Alleviates SU5416/Hypoxia-Induced Pulmonary Arterial Hypertension by Ameliorating Dysfunction of Pulmonary Arterial Smooth Muscle Cells. *Drug Des Devel Ther.* **15**:1653-1666. doi: 10.2147/DDDT.S297500.
2. Liu, Y. et al. (2021). 20-HETE-promoted cerebral blood flow autoregulation is associated with enhanced pericyte contractility. *Prostaglandins Other Lipid Mediat.* **154**:106548. doi: 10.1016/j.prostaglandins.2021.106548.
3. Kim, G.R. et al. (2021). MicroRNA-212-5p and its target PAFAH1B2 suppress vascular proliferation and contraction via the downregulation of RhoA. *PLoS One.* **16**(3):e0249146. doi: 10.1371/journal.pone.0249146.

4. Uemura, M. et al. (2021). Monophasic Pulsed Current Stimulation of Duty Cycle 10% Promotes Differentiation of Human Dermal Fibroblasts into Myofibroblasts. *Phys Ther Res*. doi: 10.1298/ptr.E10064.
5. Bai, L. et al. (2020). HDAC5 inhibition reduces angiotensin II-induced vascular contraction, hypertrophy, and oxidative stress in a mouse model. *Biomed Pharmacother*. **134**:111162. doi: 10.1016/j.biopha.2020.111162.
6. Maun, H.R. et al. (2020). Bivalent antibody pliers inhibit β -tryptase by an allosteric mechanism dependent on the IgG hinge. *Nat Commun*. **11**(1):6435. doi: 10.1038/s41467-020-20143-x.
7. Pedowitz, N.J. et al. (2020). MYPT1 O-GlcNAc modification regulates sphingosine-1-phosphate mediated contraction. *Nat Chem Biol*. doi: 10.1038/s41589-020-0640-8.
8. Yan, D. et al. (2020). Mesothelial Cells Participate in Endometriosis Fibrogenesis Through Platelet-Induced Mesothelial-Mesenchymal Transition. *J Clin Endocrinol Metab*. doi: 10.1210/clinem/dgaa550.
9. Ilg, M.M. et al. (2020). Phosphodiesterase Type 5 Inhibitors and Selective Estrogen Receptor Modulators Can Prevent But Not Reverse Myofibroblast Transformation in Peyronie's. *J Sex Med*. S1743-6095(20)30727-X. doi: 10.1016/j.jsxm.2020.06.022.
10. Wójcik-Pszczola, K. et al. (2020). A Novel, Pan-PDE Inhibitor Exerts Anti-Fibrotic Effects in Human Lung Fibroblasts via Inhibition of TGF- β Signaling and Activation of cAMP/PKA Signaling. *Int J Mol Sci*. **21**(11):4008. doi: 10.3390/ijms21114008.
11. Lin, H. et al. (2020). Anti-fibrotic effect of iguratimod on pulmonary fibrosis by inhibiting the fibroblast-to-myofibroblast transition. *Adv Med Sci*. **65**(2):338-347. doi: 10.1016/j.advms.2020.05.006.
12. Chow, A. et al. (2020). Dasatinib inhibits peripapillary scleral myofibroblast differentiation. *Exp Eye Res*. doi: 10.1016/j.exer.2020.107999.
13. Wang, S. et al. (2020). Sex differences in the structure and function of rat middle cerebral arteries. *Am J Physiol Heart Circ Physiol*. doi: 10.1152/ajpheart.00722.2019.
14. Lee, E. et al. (2020). New screening system using Twist1 promoter activity identifies dihydrorotenone as a potent drug targeting cancer-associated fibroblasts. *Sci Rep*. **10**(1):7058. doi: 10.1038/s41598-020-63996-4.
15. Guo, Y. et al. (2020). Accelerated cerebral vascular injury in diabetes is associated with vascular smooth muscle cell dysfunction. *Geroscience*. doi: 10.1007/s11357-020-00179-z.
16. Chen, G. et al. (2020). Monocyte Chemotactic Protein-1 Regulates Proliferation and Contractility of Human Bladder Smooth Muscle Cells Under Hydrostatic Pressure. *J Interferon Cytokine Res*. doi: 10.1089/jir.2019.0186.
17. Zhang, H. et al. (2020). Influence of dual-specificity protein phosphatase 5 on mechanical properties of rat cerebral and renal arterioles. *Physiol Rep*. **8**(2):e14345. doi: 10.14814/phy2.14345.
18. Jeong, H. et al. (2020). Sustained Nitric Oxide-Providing Small Molecule and Precise Release Behavior Study for Glaucoma Treatment. *Mol Pharm*. doi: 10.1021/acs.molpharmaceut.9b01137.
19. Navarro, J. et al. (2019). In Vivo Evaluation of 3D Printed, Keratin-Based Hydrogels in a Porcine Thermal Burn Model. *Tissue Eng Part A*. doi: 10.1089/ten.TEA.2019.0181.
20. Malhotra, R. et al. (2019). HDAC9 is implicated in atherosclerotic aortic calcification and affects vascular smooth muscle cell phenotype. *Nat Genet*. doi: 10.1038/s41588-019-0514-8.
21. Shao, T. et al. (2019). Research on Function and Mechanisms of a Novel Small Molecule WG449E for Hypertrophic Scar. *J Eur Acad Dermatol Venereol*. doi: 10.1111/jdv.16028.

22. Heffer, A.M. et al. (2019). The polyether ionophore salinomycin targets multiple cellular pathways to block proliferative vitreoretinopathy pathology. *PLoS One*. **14**(9):e0222596. doi: 10.1371/journal.pone.0222596.
23. Esteban-Vives, R. et al. (2019). Isolation and Characterization of a Human Fetal Mesenchymal Stem Cell Population: Exploring the Potential for Cell Banking in Wound Healing Therapies. *Cell Transplant*. doi: 10.1177/0963689718817524.
24. Wen, J. et al. (2019). Inhibition of LPA1 Signaling Impedes Conversion of Human Tenon's Fibroblasts into Myofibroblasts Via Suppressing TGF- β /Smad2/3 Signaling. *J Ocul Pharmacol Ther*. **35**(6):331-340. doi: 10.1089/jop.2018.0120.
25. Canugovi, C. et al. (2019). Increased mitochondrial NADPH oxidase 4 (NOX4) expression in aging is a causative factor in aortic stiffening. *Redox Biology*. doi:10.1016/j.redox.2019.101288.
26. Lai, J. et al. (2019). β -Adrenoceptor signaling regulates proliferation and contraction of human bladder smooth muscle cells under pathological hydrostatic pressure. *J Cell Biochem*. doi: 10.1002/jcb.29056.
27. Chen, L. et al. (2019). Increased Complement 3 With Suppression of miR-145 Induces the Synthetic Phenotype in Vascular Smooth Muscle Cells From Spontaneously Hypertensive Rats. *J Am Heart Assoc*. **8**(10):e012327. doi: 10.1161/JAHA.119.012327.
28. Yan, D. et al. (2019). Neuropeptides Substance P and Calcitonin Gene Related Peptide Accelerate the Development and Fibrogenesis of Endometriosis. *Sci Rep*. **9**(1):2698. doi: 10.1038/s41598-019-39170-w.
29. Cavin, S. et al. (2019). Vascular-targeted low dose photodynamic therapy stabilizes tumor vessels by modulating pericyte contractility. *Lasers Surg Med*. doi: 10.1002/lsm.23069.
30. Tsou, P.S. et al. (2019). Inhibition of EZH2 prevents fibrosis and restores normal angiogenesis in scleroderma. *Proc Natl Acad Sci U S A*. **116**(9):3695-3702. doi: 10.1073/pnas.1813006116.

Warranty

These products are warranted to perform as described in their labeling and in Cell Biolabs literature when used in accordance with their instructions. THERE ARE NO WARRANTIES THAT EXTEND BEYOND THIS EXPRESSED WARRANTY AND CELL BIOLABS DISCLAIMS ANY IMPLIED WARRANTY OF MERCHANTABILITY OR WARRANTY OF FITNESS FOR PARTICULAR PURPOSE. CELL BIOLABS' sole obligation and purchaser's exclusive remedy for breach of this warranty shall be, at the option of CELL BIOLABS, to repair or replace the products. In no event shall CELL BIOLABS be liable for any proximate, incidental or consequential damages in connection with the products.

Contact Information

Cell Biolabs, Inc.
7758 Arjons Drive
San Diego, CA 92126
Worldwide: +1 858-271-6500
USA Toll-Free: 1-888-CBL-0505
E-mail: tech@cellbiolabs.com
www.cellbiolabs.com

©2004-2021: Cell Biolabs, Inc. - All rights reserved. No part of these works may be reproduced in any form without permissions in writing.